Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 17/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31113937 | 0.96 | F2RL3 (0.50) | F2RL3DYRK1A | |
| SCHEMBL21396093 | 0.96 | F2RL3 (0.50) | F2RL3DYRK1A | |
| SCHEMBL23462961 | 0.94 | F2RL3 (0.43) | F2RL3 | |
| SCHEMBL31113797 | 0.94 | F2RL3 (0.43) | F2RL3 | |
| SCHEMBL31113479 | 0.91 | F2RL3 (0.45) | F2RL3 | |
| SCHEMBL21395834 | 0.91 | F2RL3 (0.45) | F2RL3 | |
| SCHEMBL21379346 | 0.91 | F2RL3 (0.48) | F2RL3DYRK1AAGPAT2 | |
| SCHEMBL23405339 | 0.91 | F2RL3 (0.48) | F2RL3DYRK1AAGPAT2 | |
| SCHEMBL21379343 | 0.91 | F2RL3 (0.48) | F2RL3DYRK1AAGPAT2 | |
| SCHEMBL21379511 | 0.90 | F2RL3 (0.47) | F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | F2RL3 2/4885DYRK1A 645/4885CLK1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.